Cargando…
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, affects approximately 75 to 100 million Americans. Patients with concurrent NAFLD and type 2 diabetes mellitus have a higher risk of progressing to advanced fibrosis and non-alcoholic steatohepatitis compared to non-d...
Autores principales: | Snyder, Heather S., Sakaan, Sami A., March, Katherine L., Siddique, Osama, Cholankeril, Rosann, Cummings, Carolyn D., Gadiparthi, Chiran, Satapathy, Sanjaya K., Ahmed, Aijaz, Cholankeril, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
XIA & HE Publishing Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018310/ https://www.ncbi.nlm.nih.gov/pubmed/29951362 http://dx.doi.org/10.14218/JCTH.2017.00050 |
Ejemplares similares
-
An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease
por: Perumpail, Brandon J., et al.
Publicado: (2017) -
Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates
por: Gadiparthi, Chiranjeevi, et al.
Publicado: (2018) -
Nonalcoholic Fatty Liver Disease: Epidemiology, Liver Transplantation Trends and Outcomes, and Risk of Recurrent Disease in the Graft
por: Liu, Andy, et al.
Publicado: (2018) -
Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
por: Dibba, Pratima, et al.
Publicado: (2018) -
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
por: Cholankeril, George, et al.
Publicado: (2017)